Quick Answer
Indaptus Therapeutics, Inc. reported Common Stock Shares Outstanding of 2.17 million shares for the year ending 2025.
- Indaptus Therapeutics, Inc. showed an increase of +258.3% in Common Stock Shares Outstanding from 2025 to 2025.
- This data is from Indaptus Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: 1.86 million shares | Q3 2021: 8.13 million shares | Q1 2022: 8.26 million shares | Q2 2022: 8.26 million shares | Q3 2022: 8.26 million shares | Q1 2023: 8.40 million shares | Q2 2023: 8.40 million shares | Q3 2023: 8.40 million shares | Q1 2024: 8.54 million shares | Q2 2024: 8.55 million shares | Q3 2024: 10.20 million shares | Q1 2025: 16.03 million shares | Q3 2025: 1.64 million shares.
- Over the full 7 years of available data (2020 to 2025), Indaptus Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 11.4%.
- Historical annual values: Fiscal year 2025: 2.17 million shares | Fiscal year 2025: 604,963 shares | Fiscal year 2024: 428,799 shares | Fiscal year 2023: 8.40 million shares | Fiscal year 2022: 8.40 million shares | Fiscal year 2021: 8.26 million shares | Fiscal year 2020: 1.94 million shares.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: